International Assets Investment Management LLC Has $8.15 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

International Assets Investment Management LLC lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11,244.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,935 shares of the medical equipment provider's stock after acquiring an additional 66,345 shares during the period. International Assets Investment Management LLC's holdings in Zimmer Biomet were worth $8,146,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Clear Street Markets LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $27,000. Lazard Asset Management LLC lifted its holdings in shares of Zimmer Biomet by 70.5% during the third quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 117 shares during the period. Dark Forest Capital Management LP acquired a new stake in shares of Zimmer Biomet during the first quarter worth $35,000. Activest Wealth Management lifted its holdings in shares of Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 275 shares during the period. Finally, Peoples Bank KS acquired a new stake in shares of Zimmer Biomet during the third quarter worth $48,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ZBH shares. Citigroup raised their target price on Zimmer Biomet from $134.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, April 3rd. Canaccord Genuity Group reissued a "hold" rating and issued a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. Barclays raised their price target on Zimmer Biomet from $120.00 to $130.00 and gave the company an "underweight" rating in a research report on Monday, February 12th. Truist Financial raised their price target on Zimmer Biomet from $133.00 to $135.00 and gave the company a "hold" rating in a research report on Friday, February 9th. Finally, Evercore ISI raised their price target on Zimmer Biomet from $125.00 to $130.00 and gave the company an "in-line" rating in a research report on Thursday, April 4th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $139.39.

Zimmer Biomet Stock Performance

Shares of ZBH stock traded down $3.04 on Friday, hitting $124.48. 1,048,564 shares of the stock traded hands, compared to its average volume of 1,130,065. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. The company has a market capitalization of $25.58 billion, a PE ratio of 25.46, a PEG ratio of 2.29 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $149.25. The company's fifty day moving average is $126.73 and its 200 day moving average is $118.94.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.05. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The business's revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.88 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.77%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet's dividend payout ratio is presently 19.63%.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company's stock, valued at $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.